{"id":"placebo-adt","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Hot flashes"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"30-60%","effect":"Loss of libido"},{"rate":"20-50%","effect":"Erectile dysfunction"},{"rate":"10-30%","effect":"Osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL255609","moleculeType":"Small molecule","molecularWeight":"252.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADT works by targeting the androgen receptor, which is a protein that helps regulate the growth of prostate cancer cells. By blocking the androgen receptor, ADT can slow or stop the growth of prostate cancer cells. In the context of this treatment, the placebo serves as a control group to compare the effectiveness of ADT.","oneSentence":"Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:33.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT07463092","phase":"NA","title":"Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03","conditions":"Prostate Cancer, Sarcopenia","enrollment":34},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT06957691","phase":"PHASE2","title":"Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"Shehzad Basaria, M.D.","startDate":"2026-01-14","conditions":"Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease","enrollment":60},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT01410942","phase":"PHASE2","title":"Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-08","conditions":"Prostate Cancer","enrollment":175},{"nctId":"NCT05593029","phase":"PHASE2","title":"A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-09","conditions":"Major Depressive Disorder","enrollment":929},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT06846320","phase":"PHASE2","title":"Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-29","conditions":"Generalized Anxiety Disorder (GAD)","enrollment":315},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT05838716","phase":"PHASE3","title":"Vitamin D for Prostate Endocrine Therapy","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2023-12-14","conditions":"Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":240},{"nctId":"NCT03371719","phase":"PHASE2","title":"Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2018-06-20","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":324},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT03753334","phase":"PHASE2","title":"Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2017-07-10","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT03496805","phase":"PHASE2","title":"Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-01-29","conditions":"Recurrent Prostate Cancer","enrollment":106},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT05595213","phase":"NA","title":"Wrist Cooling for Hot Flashes Clinical Trial","status":"COMPLETED","sponsor":"Boston University","startDate":"2023-03-05","conditions":"Hot Flashes","enrollment":27},{"nctId":"NCT06861192","phase":"PHASE2, PHASE3","title":"Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-02-16","conditions":"Prostate CA","enrollment":83},{"nctId":"NCT04855747","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Levomecor Inc.","startDate":"2021-03-30","conditions":"Major Depressive Disorder, Depression","enrollment":236},{"nctId":"NCT06011577","phase":"PHASE3","title":"Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD","status":"TERMINATED","sponsor":"Levomecor Inc.","startDate":"2023-08-17","conditions":"Major Depressive Disorder, Depression","enrollment":27},{"nctId":"NCT02677896","phase":"PHASE3","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-03-09","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":1150},{"nctId":"NCT02294461","phase":"PHASE3","title":"An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04-23","conditions":"Progressive Metastatic Prostate Cancer","enrollment":395},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT06834321","phase":"PHASE2","title":"Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-03-19","conditions":"Prostate CA","enrollment":96},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT07057375","phase":"NA","title":"The Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-06-01","conditions":"Prostate Cancer","enrollment":110},{"nctId":"NCT05191680","phase":"PHASE2","title":"TherApeutics in Early ProState Cancer (TAPS02)","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2023-04-24","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT04743934","phase":"PHASE2","title":"Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew McDonald","startDate":"2021-07-02","conditions":"Prostate Adenocarcinoma","enrollment":44},{"nctId":"NCT06931275","phase":"NA","title":"Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes","status":"RECRUITING","sponsor":"T1D Exchange, United States","startDate":"2024-08-13","conditions":"Diabetes Mellitus, Type 1","enrollment":1178},{"nctId":"NCT04600336","phase":"PHASE2","title":"Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-28","conditions":"Prostate Carcinoma","enrollment":88},{"nctId":"NCT06643494","phase":"PHASE1, PHASE2","title":"Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical","status":"SUSPENDED","sponsor":"Optimal Health Research","startDate":"2024-08-15","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT05348577","phase":"PHASE3","title":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-25","conditions":"Prostate Cancer","enrollment":1035},{"nctId":"NCT03031821","phase":"PHASE3","title":"Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome","status":"TERMINATED","sponsor":"Canadian Urologic Oncology Group","startDate":"2018-07-12","conditions":"Prostate Cancer, Metabolic Syndrome","enrollment":168},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT05116475","phase":"PHASE3","title":"Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases","status":"RECRUITING","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2022-08-30","conditions":"Prostate Cancer","enrollment":152},{"nctId":"NCT01996696","phase":"PHASE2","title":"Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2014-09","conditions":"Prostatic Neoplasm","enrollment":83},{"nctId":"NCT04476030","phase":"PHASE3","title":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-11-09","conditions":"Depressive Disorder, Major","enrollment":440},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05098327","phase":"PHASE3","title":"Pioglitazone and Insulin Resistance in ADT","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2021-08-01","conditions":"Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01555632","phase":"NA","title":"Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2012-03","conditions":"Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":""},{"nctId":"NCT04136353","phase":"PHASE3","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2020-03-31","conditions":"Prostate Cancer","enrollment":1100},{"nctId":"NCT04995978","phase":"PHASE2","title":"Insulin Resistance and Androgen Deprivation Therapy","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2021-12-01","conditions":"Prostate Cancer, Insulin Resistance","enrollment":""},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT04658849","phase":"EARLY_PHASE1","title":"Insulin Resistance Following ADT for Prostate CA","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2020-12-02","conditions":"Insulin Resistance, Prostate Cancer","enrollment":""},{"nctId":"NCT03738215","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-11-09","conditions":"Major Depressive Disorder","enrollment":759},{"nctId":"NCT04026230","phase":"PHASE3","title":"Impact of Atorvastatin on Prostate Cancer Progression During ADT","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2019-08-15","conditions":"Metastatic Prostate Cancer, Recurrent Prostate Cancer","enrollment":400},{"nctId":"NCT02766478","phase":"PHASE2","title":"Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-10-16","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT03739203","phase":"PHASE3","title":"The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-11-10","conditions":"Major Depressive Disorder","enrollment":752},{"nctId":"NCT02582749","phase":"PHASE2","title":"Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Ajjai Alva, MD","startDate":"2016-04","conditions":"Prostate Cancer, Bone Metastases, Prostate Neoplasms","enrollment":16},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT00594620","phase":"PHASE2","title":"Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy","status":"TERMINATED","sponsor":"University of Kansas Medical Center","startDate":"2004-08","conditions":"Prostate Cancer","enrollment":11},{"nctId":"NCT05009290","phase":"PHASE3","title":"A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-11-01","conditions":"Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","enrollment":1256},{"nctId":"NCT03646162","phase":"PHASE2","title":"Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Veru Inc.","startDate":"2018-09-14","conditions":"Prostate Cancer Metastatic","enrollment":93},{"nctId":"NCT05076851","phase":"PHASE2","title":"Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2021-06-17","conditions":"Neoadjuvant Therapy \\High Risk Prostate Cancer","enrollment":2},{"nctId":"NCT02497638","phase":"PHASE2","title":"LIpitor and biGuanide to Androgen Delay Trial","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2021-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04729491","phase":"PHASE2, PHASE3","title":"EAT-DUTA AndroCoV Trial","status":"COMPLETED","sponsor":"Corpometria Institute","startDate":"2020-06-30","conditions":"Covid19","enrollment":138},{"nctId":"NCT00079001","phase":"PHASE3","title":"Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-01","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":645},{"nctId":"NCT01212991","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09-16","conditions":"Prostate Cancer","enrollment":1717},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01006395","phase":"PHASE2, PHASE3","title":"Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)","status":"COMPLETED","sponsor":"Austin Health","startDate":"2011-01","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT02064946","phase":"NA","title":"High-dose Vitamin D Supplementation for ADT-induced Side Effects","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-03","conditions":"Prostatic Neoplasms, Bone Mineral Density Quantitative Trait Locus 3","enrollment":108},{"nctId":"NCT00286091","phase":"PHASE3","title":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-01-24","conditions":"Hormone Refractory Prostate Cancer","enrollment":1435},{"nctId":"NCT00089674","phase":"PHASE3","title":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Prostate Cancer","enrollment":1468},{"nctId":"NCT01837797","phase":"PHASE3","title":"Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-04","conditions":"Major Depressive Disorder","enrollment":129},{"nctId":"NCT02196506","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":837},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT02952742","phase":"PHASE2","title":"Black Cohosh for Host Flashes Due to Androgen Deprivation Therapy","status":"WITHDRAWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-11","conditions":"Hot Flashes","enrollment":""},{"nctId":"NCT00245518","phase":"PHASE4","title":"Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2005-06","conditions":"Hot Flashes","enrollment":39},{"nctId":"NCT00063609","phase":"PHASE4","title":"The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-04","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT03211104","phase":"NA","title":"Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2007-08-30","conditions":"Prostate Cancer","enrollment":107},{"nctId":"NCT00925600","phase":"PHASE3","title":"Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-30","conditions":"Cancer, Cataract, Low Bone Mineral Density","enrollment":769},{"nctId":"NCT00470834","phase":"PHASE4","title":"Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Neoplasms, Prostate","enrollment":127},{"nctId":"NCT01912196","phase":"PHASE2","title":"Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"MSI Methylation Sciences, Inc.","startDate":"2013-10","conditions":"Major Depressive Disorder (MDD)","enrollment":376},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT01360632","phase":"PHASE3","title":"Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-06","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":1539},{"nctId":"NCT01360645","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":826},{"nctId":"NCT01052077","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-03","conditions":"Major Depressive Disorder","enrollment":773},{"nctId":"NCT00684320","phase":"NA","title":"Attention Disengagement Training for Social Phobia","status":"COMPLETED","sponsor":"San Diego State University","startDate":"2006-09","conditions":"Social Anxiety Disorder","enrollment":48},{"nctId":"NCT00105196","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Major Depressive Disorder","enrollment":349},{"nctId":"NCT00129142","phase":"PHASE3","title":"Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"GTx","startDate":"2003-10","conditions":"Prostate Cancer, Osteoporosis, Fractures","enrollment":1200},{"nctId":"NCT01214291","phase":"PHASE3","title":"Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer","status":"WITHDRAWN","sponsor":"GTx","startDate":"2011-03","conditions":"Risk of Bone Fracture Occurrences","enrollment":""},{"nctId":"NCT00181584","phase":"PHASE2","title":"Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-09","conditions":"Bone Loss, Prostate Cancer","enrollment":60},{"nctId":"NCT00426777","phase":"PHASE3","title":"Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer","status":"COMPLETED","sponsor":"CMX Research","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00199485","phase":"PHASE4","title":"Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2002-10","conditions":"Prostate Cancer","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + ADT","genericName":"Placebo + ADT","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells. Used for Prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}